专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO9101970A3 CYCLIC AMIDOCARBOXY SURFACTANTS, SYNTHESIS AND USE THEREOF 审中-公开
标题翻译：循环粘土氧化物表面活性剂，合成及其用途
公开(公告)号：WO9101970A3
公开(公告)日：1992-01-09
申请号：PCT/EP9001044
申请日：1990-06-29
申请人： STEPAN CO , HOLMES MICHAEL JOHN
发明人： GOZE JEAN M , BERNHARDT RANDAL J , HARTLAGE JAMES A , SMITH NORMAN R , LIETZ DENNIS E , KAY JAMES W , BREITBEIL FRED W , SAJIC BRANCO , ROCKWELL NED MILES , MCCONNELL NINA MONTSERRAT , MOHRING WILLIAM RICHARD
IPC分类号： A01N37/22 , A01N25/30 , A01N37/18 , A23L29/00 , A23L29/10 , A61K8/00 , A61K8/31 , A61K8/34 , A61K8/37 , A61K8/41 , A61K8/42 , A61K8/44 , A61K8/60 , A61K8/89 , A61K8/891 , A61K8/92 , A61K8/97 , A61K8/98 , A61Q5/00 , A61Q5/02 , A61Q5/12 , A61Q19/00 , A61Q19/10 , B01F17/00 , B01F17/22 , B01J13/00 , C07C211/63 , C07C215/40 , C07C233/00 , C07C233/65 , C07C233/69 , C07C235/84 , C07D233/86 , C08F2/26 , C09D125/00 , C09D125/04 , C09D133/04 , C09D133/06 , C10L1/22 , C10L1/32 , C10L10/18 , C10M133/16 , C10M133/56 , C10N10/02 , C10N10/04 , C10N10/06 , C10N10/08 , C10N30/00 , C10N30/02 , C10N40/00 , C10N40/20 , C11D1/10 , C11D1/88 , C11D3/00 , D06M13/415 , D06M15/693 , A01N37/24 , A23L1/035
CPC分类号： D06M15/693 , A01N25/30 , A23L29/10 , A61K8/06 , A61K8/445 , A61Q5/006 , A61Q5/02 , A61Q5/12 , A61Q19/00 , B01F17/0042 , C07C211/63 , C07C215/40 , C07C233/65 , C07C233/69 , C08F2/26 , C10L1/328 , C11D1/10 , C11D1/88 , C11D3/001 , D06M7/00 , D06M13/415 , D06M2200/40
摘要： Cyclic amidocarboxy surfactants having general formula (I) wherein: R1 and R2 are independently selected from the group consisting essentially of H or C1-C40 linear or branched, substituted or unsubsituted alkyl, cycloalkyl, alkylene, alkaryl, aryl or R3-O-R4 groups, with R3 and R4 being independently selected from the group consisting essentially of C1-C22 linear or branched, substituted or unsubstituted alkyl, cycloalkyl, alkylene, alkaryl and aryl groups; y is an integer of a value satisfying the valency of M; and M is a cation and is preferably selected from the groups consisting of H, Na, K, NH4 [including (CH3CH2)3NH, (CH3CH2)2NH2, (HOCH2CH2)3NH, (HOCH2CH2)2NH2 and similar ammonium derivatives], Ba, Ca, Mg, Al, Ti, Zr and mixtures thereof. These surfactants are useful in a variety of technical applications, such as fast-break emulsifiers in personal care products; destructible latex polymerization surfactants in manufacture and compounding of various coating or adhesive systems; domestic fabric softening agents; foodstuff emulsifiers; caustic-stabile surfactants; bleach-stabile surfactants; various domestic detergents and hard surface cleaners, emulsifiers for portland cement and concrete; floatation/benefication agents for mining/processing various mineral ores; additives for electroplating and/or surface finishing for metal goods; additives for plaster, gypsum and miscellaneous building materials; enhanced oil recovery additives; wetting and lubricating agents for industrial textile processing; compatibilizers/surfactants for polyurethane/isocyanurate foam systems, wood pulping additives; emulsifiers for various industrial surfactant systems, such as fatty alcohol/water emulsions; pour-point depressants for transporting petroleum crude oils, suspension agents for various particulate materials, such as anti-dandruff materials, i.e., sulfur, zinc pyrithone, etc. and other particulate materials, such as pulverized coal, and other similar uses.

22. 发明申请

WO2022118951A1 化合物、重合性組成物、光学異方性膜、光学フィルム、偏光板および画像表示装置审中-公开
公开(公告)号：WO2022118951A1
公开(公告)日：2022-06-09
申请号：PCT/JP2021/044450
申请日：2021-12-03
申请人：富士フイルム株式会社
发明人：吉田　愛子 , 佐々木　晃逸 , 平井　友樹 , 森嶌　慎一 , 井本　翔
IPC分类号： C07D233/86 , C08F36/00 , C07D213/85 , C07D239/62 , C07D239/66 , C07D231/36 , C07C69/753 , G02B5/30 , G02F1/13363
摘要：本発明は、逆波長分散性に優れた光学異方性膜の形成に用いられる化合物、重合性組成物、光学異方性膜、光学フィルム、偏光板および画像表示装置を提供することを課題とする。本発明の化合物は、下記式（１）で表される化合物である。

23. 发明申请

WO2022091091A1 POLYMERIC DISINFECTANTS AND USES THEREOF 审中-公开
公开(公告)号：WO2022091091A1
公开(公告)日：2022-05-05
申请号：PCT/IL2021/051272
申请日：2021-10-27
申请人： TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
发明人： FARAH, Shady
IPC分类号： C08L39/04 , A61L2/18 , C07D233/74 , C07D233/76 , C07D233/78 , C07D233/80 , C07D233/96 , C07D233/86 , C07D237/32 , C07D239/46 , C07D239/47 , C07D239/54 , C07D239/56 , C07D239/60 , C07D239/96 , C07D249/08 , C07D251/24 , C07D403/04 , C07D403/12 , C07D473/02 , C07D473/06 , C07D473/30 , A61P31/02 , A61K31/787
摘要： The present invention relates to polymers comprising bifunctional mono- or polycyclic heterocyclic or heteroaromatic repeating units having disinfecting activity, compositions thereof, and methods for disinfecting surfaces utilizing said compositions.

24. 发明申请

WO2022076611A1 NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2022076611A1
公开(公告)日：2022-04-14
申请号：PCT/US2021/053846
申请日：2021-10-06
申请人： THE PENN STATE RESEARCH FOUNDATION
发明人： MISRA, Sougat
IPC分类号： A61K31/4166 , A61K45/06 , C07D233/86
摘要： Disclosed herein are compositions and methods for increasing the expression of human SLC7A11. The compositions include a combination of compounds that exhibit anti-proliferative activity against cancer cells. The compositions and methods can be used to treat a subject with cancer. Disclosed are also compositions and methods of treating a coronavirus infection, Zika virus, influenza virus infection, human immunodeficiency virus (HIV), or Rhinovirus.

25. 发明申请

WO2020032268A1 硫黄含有重合性単量体およびその用途审中-公开
公开(公告)号：WO2020032268A1
公开(公告)日：2020-02-13
申请号：PCT/JP2019/031707
申请日：2019-08-09
申请人：サンメディカル株式会社 , 三井化学株式会社
发明人：松村　英雄 , 宮森　沙耶香 , 山本　隆司 , 吉永　一彦 , 三尾　茂 , 清野　真二 , 鈴木　比捺
IPC分类号： C07D233/86 , A61K6/00
摘要：式（１）で表される化合物（Ａ）。［式（１）中、Ｒ 1 は、水素原子またはアルカリ金属原子であり、Ｒ 2 は、水素原子またはアルカリ金属原子であり、Ｒ 3 は、水素原子またはメチル基であり、Ｚは、２価または３価の有機基であり、Ｚに結合する実線および破線からなる線は、単結合または二重結合を表す。］

26. 发明申请

WO2019196945A1 一种合成氘代酰胺及氘代磺酰胺的新方法审中-公开
公开(公告)号：WO2019196945A1
公开(公告)日：2019-10-17
申请号：PCT/CN2019/082555
申请日：2019-04-12
申请人：成都海创药业有限公司
发明人：杜武 , 温坤 , 何锦云 , 李海波 , 秦德锟 , 李兴海 , 陈元伟
IPC分类号： C07B43/06 , C07D233/86 , C07D401/04 , C07D401/06 , C07C231/10 , C07C233/65 , C07C233/58 , C07C233/11 , C07C233/05
摘要：公开了一种合成氘代酰胺及氘代磺酰胺的新方法，步骤如下：(1)将化合物M、DMAP、R 3 -X加入到溶剂中，反应完全后得化合物N；(2)将化合物N、R 4 -NH-R 5 或其盐、碱加入到溶剂中，反应完全后，纯化得化合物Ⅰ。该方法反应条件温和，路线短，仅需两步即可得到，可以应用于已有方法不能适用的原料，提高合成效率，可以适用于很多酰胺类化合物，具有较强的普适性，为制备氘代胺的酰胺及磺酰胺类化合物提供了一种新的选择。

27. 发明申请

WO2017120218A1 TREATMENT OF PROSTATE CANCER CELLS WITH FAT OXIDATION INHIBITORS AND ENZALUTAMIDE 审中-公开
标题翻译：脂肪氧化抑制剂和苯甲酰胺治疗前列腺癌细胞
公开(公告)号：WO2017120218A1
公开(公告)日：2017-07-13
申请号：PCT/US2017/012167
申请日：2017-01-04
申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE , SCHLAEPFER, Isabel Rubio
发明人： SCHLAEPFER, Isabel Rubio
IPC分类号： A61K31/58 , A61K31/277 , A61K31/355 , A61K31/495 , A61K31/4402 , C07D233/86 , C07J43/00
CPC分类号： A61K31/277 , A61K31/336 , A61K31/4166 , A61K31/4458 , A61K31/495 , A61K31/58 , A61K45/06 , C07J43/003 , A61K2300/00
摘要： A combination therapy for the treatment of cancers refractory to anti-androgen therapy; particularly prostate cancer. The combination therapy includes a pharmaceutically effective amount of enzalutamide, bicalutamide, and/or abiraterone combination with ranolazine, perhexiline, and/or etomoxir. The invention also includes methods for treating cancer. The method can include the steps of administering to the subject a pharmaceutically effective amount of an anti-androgen drug in combination with a pharmaceutically effective amount of a drug that block or reduces lipid metabolism. The cancer can be prostate cancer. In a beneficial embodiment the prostate cancer is unresponsive or has a reduced responsiveness to anti-androgen treatment. The pharmaceutically effective amount of an anti-androgen drug can enzalutamide and abiraterone. It can also be combinations, analogs and derivatives of enzalutamide and/or abiraterone. The pharmaceutically effective amount of a drug that blocks or reduces lipid metabolism can be ranolazine, perhexiline, or etomoxir. It can also be combinations, analogs and derivatives of ranolazine, perhexiline, and/or etomoxir.
摘要翻译：用于治疗抗雄激素疗法难治的癌症的组合疗法; 特别是前列腺癌。组合疗法包括药学有效量的恩氮鲁胺，比卡鲁胺和/或阿比特龙与雷诺嗪，哌可昔林和/或艾莫考昔的组合。本发明还包括治疗癌症的方法。该方法可包括向受试者施用药学有效量的抗雄激素药物以及药学有效量的阻断或降低脂质代谢的药物的步骤。癌症可以是前列腺癌。在有利的实施方案中，前列腺癌无反应或对抗雄激素治疗的反应性降低。抗雄激素药物的药学有效量可以是恩佐鲁胺和阿比特龙。它也可以是恩扎鲁胺和/或阿比特龙的组合，类似物和衍生物。阻断或降低脂质代谢的药物的药学有效量可以是雷诺嗪，perhexiline或者etomoxir。它也可以是雷诺嗪，哌可昔林和/或乙莫克昔的组合，类似物和衍生物。

28. 发明申请

WO2017081702A2 A PROCESS FOR PREPARATION OF ENZALUTAMIDE 审中-公开
标题翻译：一种制备恩扎鲁胺的方法
公开(公告)号：WO2017081702A2
公开(公告)日：2017-05-18
申请号：PCT/IN2016/050388
申请日：2016-11-08
申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED
发明人： THENNATI, Rajamannar , DWIVEDI, Shriprakash Dhar , YADAV, Arunkumar Gulabsingh , PATEL, Nischalkumar Vinodbhai , KARANKE, Sunil Rajaram
IPC分类号： C07D233/86
CPC分类号： C07D233/86
摘要： The present invention relates to an improved process for preparation of enzalutamide which involves direct condensation of 2-(4-alkoxycarbonyl-3-fluoro-anilino)-2-methyl-propanoic acid and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile to obtain alkyl 4-[3-(4-cyano-3- methyl-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-benzoate, which is further converted to enzalutamide.
摘要翻译：本发明涉及用于制备恩扎鲁胺的改进方法，其涉及2-（4-烷氧基羰基-3-氟 - 苯胺基）-2-甲基 - 丙酸和4-异硫氰酸基 - 丙酸的直接缩合，（三氟甲基）苄腈反应，得到4- [3-（4-氰基-3-甲基 - 苯基）-5,5-二甲基-4-氧代-2-硫代 - 咪唑烷-1-基] -2-氟苯甲酸酯，后者进一步转化为enzalutamide。

29. 发明申请

WO2016079522A1 ANDROGEN RECEPTOR MODULATORS AND THEIR USE AS ANTI-CANCER AGENTS 审中-公开
标题翻译：雄激素受体调节剂及其作为抗癌剂的用途
公开(公告)号：WO2016079522A1
公开(公告)日：2016-05-26
申请号：PCT/GB2015/053528
申请日：2015-11-19
申请人： UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
发明人： WESTWELL, Andrew D , PERTUSATI, Fabrizio , MCGUIGAN, Christopher , BRANCALE, Andrea , BASSETTO, Marcella , FERLA, Salvatore , KANDIL, Sahar
IPC分类号： C07D233/86 , C07C233/01 , A61K31/4166 , A61P35/00
CPC分类号： C07D233/86 , C07C381/00
摘要： Compounds having therapeutic potential as androgen receptor modulators and anti- cancer agents, and methods of making such compounds, are provided. The compounds are structurally related to bicalutamide, enobosarm and enzalutamide, but bear at least one SF 5 group as a substituent.
摘要翻译：提供具有作为雄激素受体调节剂和抗癌剂的治疗潜力的化合物，以及制备这些化合物的方法。这些化合物在结构上与比卡鲁胺，恩佐沙坦和恩扎拉平有关，但至少有一个SF5基团作为取代基。

30. 发明申请

WO2015042029A1 COMBINATION DRUG THERAPY 审中-公开
标题翻译：组合药物治疗
公开(公告)号：WO2015042029A1
公开(公告)日：2015-03-26
申请号：PCT/US2014/055816
申请日：2014-09-16
申请人： GLAXOSMITHKLINE LLC
发明人： GRESHOCK, Joel , BACHMAN, Kurtis Earl , BLACKMAN, Samuel Charles
IPC分类号： A61K31/4166 , A61K31/535 , C07D233/86 , C07D413/10
CPC分类号： A61K31/5377 , A61K31/4166 , A61K31/535 , A61K2300/00
摘要： A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro- N- methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a PI3Kß inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or PI3Kß is beneficial, e.g., cancer.
摘要翻译：包含雄激素受体抑制剂，4-（3-（4-氰基-3-（三氟甲基）苯基）-5,5-二甲基-4-氧代-2-硫代咪唑烷-1-基）-2-氟 - N-甲基苯甲酰胺或其药学上可接受的盐或溶剂合物与PI3Kβ抑制剂，2-甲基-1 - {[2-甲基-3-（三氟甲基）苯基]甲基} -6-（4-吗啉基）-1H-苯并咪唑 -4-羧酸或其药学上可接受的盐，包含该组合物的药物组合物以及使用这些组合和组合物治疗雄激素受体和/或PI3Kβ抑制作用的条件（例如癌症）的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式